NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$0.49 USD
-0.01 (-1.52%)
Updated Aug 30, 2024 03:58 PM ET
After-Market: $0.49 0.00 (0.68%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
NovaBay Pharmaceuticals, Inc. [NBY]
Reports for Purchase
Showing records 1 - 20 ( 109 total )
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Coronavirus Vol. 31: Novartis Goes All in on Hydroxychloroquine for COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
2018 Financial Results Reported; Reiterate Neutral and Lower Price Target to $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Strategic Shift, Management Shakeup; Downgrading to Neutral; Reducing Price Target to $1.25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are dropping coverage of NBY to reallocate research resources
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Preliminary 2018 Financial Results Reported; Reiterate Buy and Reduce Price Target to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q18 Financial Results Reported; Reiterate Buy and Reduce Price Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q18 Financial Results Reported; Revenue Miss, Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Sales Team Expanded; 2Q18 Revenue Lower Than Expected; Reiterate Buy and Lowering Target to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q 2018 Results Reported; Reiterate Buy and Lowering Price Target to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
2017 Revenue Shows 53% Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R